The German pharmaceutical company Dr. August Wolff GmbH & Co. KG Arzneimittel Arzneimittel (“Dr. Wolff”) and the Spanish pharmaceutical company Cantabria Labs (“Cantabria Labs”) concluded a strategic partnership on March 12th 2021 by entering into an exclusive licensing agreement for a newly developed medicinal product for the treatment of hyperhidrosis. Under the terms of the license agreement, Cantabria Labs will have the exclusive right to commercialize an oil-in-water cream with 1 % glycopyrronium bromide (GPB) in Spain, Italy and Portugal. In return, Dr. Wolff Group will receive upfront, milestone as well as royalty payments and will additionally be the exclusive
The post Dr. August Wolff and Cantabria Labs enter into an exclusive commercialization agreement for Southern Europe for hyperhidrosis product appeared first on Pharma Mirror Magazine.
